Amicus Therapeutics (NASDAQ:FOLD) has grabbed attention from the analysts, when it saw a value decrease of -1.97% or -0.17 points in the last trading session to close at $8.46. A total of 1.77 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 2.36 Million shares, while its relative volume stands at 0.75. Amicus Therapeutics (NASDAQ:FOLD) has a market cap of $1.2 Billion and the number of outstanding shares have been calculated 142.26 Million.
Shares of Amicus Therapeutics (NASDAQ:FOLD) currently have an Average Brokerage Recommendation of 1, number of Recs in ABR is 6 while industry rank of the company by ABR is 168 out of 265. Out of the analyst recommendations 3 rate Amicus Therapeutics (NASDAQ:FOLD) stock a Buy, 3 rate the stock Outperform, 0 rate Hold, 0 rate Underperform and 0 recommend a Sell.
Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $12.92 on the stock, this valuation is based on 6 number of opinions. The most optimistic analyst sees the stock reaching $18 while the most conventional has $10 target price.
In order to check on the sell-side rational, we can also take a peek at some technical indicators. Amicus Therapeutics (NASDAQ:FOLD)’s price sits 12.2% above from its 50-day moving average of $7.75 and 22.2% far from the stock’s 200-day moving average which is $6.64. Stock’s twelve month price oscillated between $9.61 and $4.41. The stock hit its twelve month high on 11/15/16, and twelve month low on 12/22/16. The Average True Range, a measure of volatility is at 0.4, however its weekly and monthly volatility is 4.37%, 5.37% respectively. The company’s Relative Strength Index which shows price strength currently stands at 61.01.
Amicus Therapeutics (NASDAQ:FOLD) as of recent trade, has shown weekly upbeat performance of 0.71% which was maintained at 23.32% in 1-month period. During the past three months the stock gain 12.05%, bringing six months performance to 44.37%. Yearly performance of the stock shows a bullish trend of 26.08% while year-to-date (YTD) performance reflected 70.22% positive outlook.
While taking a glance at financials, we can look at a number of key indicators. Amicus Therapeutics (NASDAQ:FOLD) has trailing twelve month Return on Assets of -21.9%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of -63% and a Return on Investment of -37.2%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.
While having a peek at profitability ratios Amicus Therapeutics (NASDAQ:FOLD) has trailing twelve month gross margin at 82.4%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%.
However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0. The company’s forward price to earnings ratio for next fiscal year is 0. Amicus Therapeutics (NASDAQ:FOLD)’s price to free cash flow for trailing twelve months is 0. Its beta value stands at 1.78.
The company’s quick ratio for most recent quarter is 2.7 along with current ratio for most recent quarter of 2.7. Total debt to equity ratio of the company for most recent quarter is 0.5 whereas long term debt to equity ratio for most recent quarter is 0.5.